These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7817846)

  • 1. [Lack of involuntary abnormal movements in untreated schizophrenic patients].
    Hernán Silva I; Jerez CS; Ruiz TA; Seguel LM; Court LJ; Labarca BR
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1994; 22(5):200-2. PubMed ID: 7817846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Positive" and "negative" movement disorders in schizophrenia.
    Sandyk R; Kay SR
    Int J Neurosci; 1992 Oct; 66(3-4):143-51. PubMed ID: 1305614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of spontaneous dyskinesia in schizophrenia.
    Fenton WS
    J Clin Psychiatry; 2000; 61 Suppl 4():10-4. PubMed ID: 10739325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Increased blink rate in schizophrenic patients].
    Mackert A; Woyth C; Flechtner KM; Frick K
    Nervenarzt; 1990 Jul; 61(7):426-30. PubMed ID: 1975431
    [No Abstract]   [Full Text] [Related]  

  • 5. Historical perspective on movement disorders.
    Friedman JH
    J Clin Psychiatry; 2004; 65 Suppl 9():3-8. PubMed ID: 15189105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors related to the severity of tardive dyskinesia.
    Wade JB; Hart RP; Dougherty LM
    Brain Cogn; 1993 Sep; 23(1):71-80. PubMed ID: 8105823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Schizophrenic deficit syndrome and neurologic tolerance].
    Verdoux H; Bourgeois M
    Encephale; 1996 Jun; 22 Spec No 2():45-7. PubMed ID: 8767042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Masking of tardive dyskinesia with four times-a-day administration of chlorpromazine.
    Jeste DV; Olgiati SG; Ghali AY
    Dis Nerv Syst; 1977 Sep; 38(9):755-8. PubMed ID: 902564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population.
    Hitzeroth A; Niehaus DJ; Koen L; Botes WC; Deleuze JF; Warnich L
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):664-72. PubMed ID: 17291655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
    Lerner V; Kaptsan A; Miodownik C; Kotler M
    Clin Neuropharmacol; 1999; 22(4):241-3. PubMed ID: 10442256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of akathisia in patients receiving stable doses of clozapine.
    Chengappa KN; Shelton MD; Baker RW; Schooler NR; Baird J; Delaney J
    J Clin Psychiatry; 1994 Apr; 55(4):142-5. PubMed ID: 7915271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organic brain dysfunction and cognitive deficits in young schizophrenic patients with tardive dyskinesia.
    Pourcher E; Cohen H; Cohen D; Baruch P; Bouchard RH
    Brain Cogn; 1993 Sep; 23(1):81-7. PubMed ID: 8105825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of neuroleptic dose and tardive dyskinesia to attention, information-processing, and psychophysiology in medicated schizophrenics.
    Spohn HE; Coyne L; Lacoursiere R; Mazur D; Hayes K
    Arch Gen Psychiatry; 1985 Sep; 42(9):849-59. PubMed ID: 2864028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients.
    Kang SG; Choi JE; An H; Park YM; Lee HJ; Han C; Kim YK; Kim SH; Cho SN; Joe SH; Jung IK; Kim L; Lee MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1844-7. PubMed ID: 18790709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.
    Schultz SK; Miller DD; Arndt S; Ziebell S; Gupta S; Andreasen NC
    Biol Psychiatry; 1995 Dec; 38(11):713-9. PubMed ID: 8580223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Exacerbation of catatonic symptoms in neuroleptic therapy].
    Bräunig P; Krüger S; Höffler J
    Nervenarzt; 1995 May; 66(5):379-82. PubMed ID: 7609820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blink rate and blunted affect among chronic schizophrenic patients.
    Kitamura T; Kahn A; Kumar R; Mackintosh JH
    Biol Psychiatry; 1984 Mar; 19(3):429-34. PubMed ID: 6722233
    [No Abstract]   [Full Text] [Related]  

  • 20. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.